Evidence map›Paper›PMID 29667478›Full record

ArticleDrug delivery2018

Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.

Mengyu Zhang, Mingxing Zhang, Jing Wang, Qingqing Cai, Ran Zhao, Yi Yu, Haiyan Tai, Xiaoyan Zhang, Congjian Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Recent Applications of Retro-Inverso Peptides.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mengyu Zhanga Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Mingxing Zhanga Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Jing Wanga Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Qingqing Caia Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Ran Zhaoa Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Yi Yua Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Haiyan Taia Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.
Xiaoyan Zhanga Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.ORCID http://orcid.org/0000-0001-9262-7473
Congjian Xua Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.ORCID http://orcid.org/0000-0002-7954-5892
Obstetrics and Gynecology Hospital of Fudan University · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of nanoparticle drug delivery systems with targeted ligands has the potential to increase treatment efficiency in ovarian cancer.

methodsWe developed a 21-amino acid peptide, YTRDLVYGDPARPGIQGTGTF (L-FP21) conjugated to polyethylenimine (PEI) and methoxy polyethylene glycol (mPEG) to prepare a nanoparticle drug vehicle to target follicle-stimulating hormone receptor (FSHR) in ovarian cancer. At the same time, we optimized the ligand of the nanoparticle vehicle using D-peptides, which consist of D-amino acids (D-FP21). Nanoparticle vehicles carrying the therapeutic gene plasmid growth-regulated oncogene alpha (pGRO-α) short hairpin RNA (shRNA) (FP21-PEG-PEI/pGRO-α) were prepared for further investigation.

resultsCompared with L-FP21, D-FP21 exhibited improved biological stability and higher uptake rate for FSHR-expressing ovarian cancer cells. The cytotoxicity of the L, D-FP21-PEG-PEI/pGRO-α complexes were significantly lower than that of the PEI/pGRO-α complex. The nanoparticle drug with the targeted ligand showed higher transfection efficiencies and improved anti-proliferation effects for ovarian cancer cells than that without the targeted ligand (mPEG-PEI/pGRO-α). Furthermore, an in vivo evaluation of an antitumor assay indicated that D-FP21-PEG-PEI/pGRO-α inhibited the growth of tumor spheroids considerably more than L-FP21-PEG-PEI/pGRO-α; their tumor inhibition rates were 58.5% and 33.3%, respectively.

conclusionsD-FP21-PEG-PEI/plasmid DNA is a safe and efficient gene delivery vehicle for ovarian cancer targeted therapy.

Indexed as

AnimalsCell Line, TumorDrug Delivery SystemsFemaleFollicle Stimulating HormoneGenetic TherapyGene Transfer TechniquesHEK293 CellsHumansMice, Inbred BALB CMice, NudeNanoparticlesOvarian NeoplasmsPeptidesPlasmidsPolyethylene GlycolsFollicle Stimulating HormonePeptidesPolyethylene GlycolsPolyethyleneimineRNA, Small Interferingfollicle-stimulating hormonegrowth-regulated oncogene αnanoparticleOvarian carcinomaRNA interferencetargeted therapy

Identifiers

PMID29667478
PMCPMC6058519
OpenAlexW2802932065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.